Products

Infectious laryngotracheitis virus cDNA and Antigen

Cat#

Product Name

Swiss Prot#

Size

Price (US$)

Order

PN1051

Recombinant Protein-Infectious laryngotracheitis virus Envelope glycoprotein M (a.a.39 to 393)

A9Y5W9

100 µg

1195

Order

PN1052

Recombinant Protein-Infectious laryngotracheitis virus Envelope glycoprotein G (a.a.33 to 292)

A9Y5X5

100 µg

1195

Order

PN1053

Recombinant Protein-Infectious laryngotracheitis virus Envelope glycoprotein B (a.a.34 to 433)

A9Y611

100 µg

1195

Order

PN1054

Recombinant Protein-Infectious laryngotracheitis virus Glycoprotein 60 (a.a.27 to 400)

Q08403

100 µg

1195

Order

PN1055

Recombinant Protein-Infectious laryngotracheitis virus Major immediate early protein (a.a.21 to 146)

Q5BQE2

100 µg

1195

Order

PN1056

Recombinant Protein-Infectious laryngotracheitis virus Envelope glycoprotein E (a.a.32 to 320)

Q67635

100 µg

1195

Order

PN1057

Recombinant Protein-Infectious laryngotracheitis virus Envelope glycoprotein G (a.a.27 to 292)

A9Y5X3

100 µg

1195

Order

PN1058

Recombinant Protein-Infectious laryngotracheitis virus Nucleocapsid protein (a.a.51 to 532)

O56880

100 µg

1195

Order

RPN1051

cDNA-Infectious laryngotracheitis virus Envelope glycoprotein M (a.a.39 to 393)

A9Y5W9

2 µg

1770

Order

RPN1052

cDNA-Infectious laryngotracheitis virus Envelope glycoprotein G (a.a.33 to 292)

A9Y5X5

2 µg

1295

Order

RPN1053

cDNA-Infectious laryngotracheitis virus Envelope glycoprotein B (a.a.34 to 433)

A9Y611

2 µg

1995

Order

RPN1054

cDNA-Infectious laryngotracheitis virus Glycoprotein 60 (a.a.27 to 400)

Q08403

2 µg

1865

Order

RPN1055

cDNA-Infectious laryngotracheitis virus Major immediate early protein (a.a.21 to 146)

Q5BQE2

2 µg

800

Order

RPN1056

cDNA-Infectious laryngotracheitis virus Envelope glycoprotein E (a.a.32 to 320)

Q67635

2 µg

1440

Order

RPN1057

cDNA-Infectious laryngotracheitis virus Envelope glycoprotein G (a.a.27 to 292)

A9Y5X3

2 µg

1325

Order

RPN1058

cDNA-Infectious laryngotracheitis virus Nucleocapsid protein (a.a.51 to 532)

O56880

2 µg

2405

Order

Infectious laryngotracheitis virus cDNA and recombinant antigen

  • Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
  • Recombinant protein applications: Western Blot may be used for other applications determined by the user.
  • Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
  • Protein Activity: N/A
  • Protein Tag:  Contains A 6x histidine tag at N-terminus.
  • Protein Formulation: Liquid
  • Source: Produced from E. coli

Infectious laryngotracheitis virus (ILTV) is a highly contagious virus that causes a respiratory disease in chickens and other birds. The virus primarily infects the trachea and larynx, leading to symptoms such as coughing, sneezing, and respiratory distress. The infection can result in high morbidity and mortality in affected flocks, leading to significant economic losses in the poultry industry. ILTV is widely distributed globally and is considered one of the most important respiratory pathogens of chickens. The control and prevention of ILTV requires effective biosecurity measures and vaccination programs. Additionally, the study of ILTV is important in understanding the biology of the virus and its pathogenesis, which can inform the development of better control and prevention strategies.

The infectious laryngotracheitis virus (ILTV) antigen refers to a protein or substance found in or produced by the virus that triggers an immune response. The ILTV antigen can be used in the development of diagnostic tests to detect the presence of the virus in chicken populations. Additionally, the production of recombinant ILTV antigen can be used as a component in the creation of vaccines to prevent ILTV infection and the associated disease, infectious laryngotracheitis. The detection of ILTV antigen is an important tool in monitoring and controlling the spread of the virus in the poultry industry.

The infectious laryngotracheitis virus (ILTV) genome refers to the complete set of genetic material present in the virus. The genome of ILTV is composed of DNA (deoxyribonucleic acid) and is characterized by its unique nucleotide sequence. The study of the ILTV genome is important in understanding the biology of the virus, its pathogenesis, and its evolution over time. The information derived from the ILTV genome can be used to develop better diagnostic tools, vaccines, and control measures for ILTV infection in chicken populations. The virus contains several key proteins that are critical for its ability to infect and replicate within host cells. These proteins include:

Envelope glycoproteins (M, B, E, G): The envelope glycoproteins of ILTV are involved in the entry of the virus into host cells, as well as its ability to evade the host immune system. They are also important for the assembly and release of new virus particles.

Glycoprotein 60: Glycoprotein 60 is another envelope protein of ILTV that plays a role in virus entry and cell-to-cell spread.

Major immediate early protein: The major immediate early protein of ILTV is involved in the regulation of viral gene expression and replication.

Nucleocapsid protein: The nucleocapsid protein is a structural protein of ILTV that encapsulates the viral genome and is essential for virus assembly and stability.

Understanding the functions of these key proteins is crucial for the development of effective strategies for the prevention and control of ILTV infections in poultry populations. Research on ILTV and its proteins also has broader implications for the poultry industry, given the significant economic impact of ILTV and other viral pathogens.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Welcome to BitClone

Magnetic Beads Make Things Simple